Use of Ganciclovir to Treat Serious Cytomegalovirus Infections in Patients with AIDS
Infections caused by human cytomegalovirus (CMV) are a major cause of morbidity and mortality in patients with AIDS. There are no antiviral agents currently available that have been documented to be effective against infections caused by CMV. Ganciclovir (9-(2-hydroxyl-1-(hydroxymethyl)ethoxymethyl)...
Gespeichert in:
Veröffentlicht in: | The Journal of infectious diseases 1987-02, Vol.155 (2), p.323-327 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Infections caused by human cytomegalovirus (CMV) are a major cause of morbidity and mortality in patients with AIDS. There are no antiviral agents currently available that have been documented to be effective against infections caused by CMV. Ganciclovir (9-(2-hydroxyl-1-(hydroxymethyl)ethoxymethyl)guanine) is an acyclic nucleoside analogue similar in structure to acyclovir. Ganciclovir (previously called BW B759U, and also known as dihydroxy propoxymethyl guanine, DHPG, 2'-NDG, and BIOLF-62) has potent in vitro activity against human CMV (50% inhibitory concentrations (ID sub(50)), 1-5 mu M). Because of this very favorable in vitro activity against CMV, ganciclovir was studied in an open-labeled fashion in patients with AIDS who had life-threatening disseminated CMV infections. |
---|---|
ISSN: | 0022-1899 1537-6613 |
DOI: | 10.1093/infdis/155.2.323 |